Industry News
Biotechnology Industry News
Bicycle Therapeutics is letting…
Bicycle Therapeutics is letting more air out of its operations, with plans to deflate its employee count by about 30% and shelve its lead anti-cancer drug conjugate.
After delaying its review, the FDA…
After delaying its review, the FDA has rejected Aldeyra Therapeutics’ experimental dry eye disease treatment for the third time.
A phase 2 study of Pfizer’s…
A phase 2 study of Pfizer’s atirmociclib has hit its primary endpoint, providing evidence that the CDK4 inhibitor improves progression-free survival in second-line metastatic breast cancer. But the Big Pharma is already looking past the
BioVie is eyeing a $19.7 million…
BioVie is eyeing a $19.7 million IPO for a spinout focused on bringing a new formulation of an approved low blood pressure drug to market as a potential treatment for liver disease.
Swiss pharma Roche is staying in…
Swiss pharma Roche is staying in lockstep with Eli Lilly, expanding its AI offerings and Nvidia partnership shortly after the latter drugmaker unveiled an Nvidia supercomputer.
Astellas is pulling out of its…
Astellas is pulling out of its $1.6 billion biobucks partnership with CytomX six years after the two companies set out to explore T-cell-engaging bispecifics for the treatment of solid tumors.
Structure Therapeutics has touted…
Structure Therapeutics has touted the 16% weight loss seen by aleniglipron as the best results yet for an oral GLP-1 drug, as the obesity biotech readies the candidate for phase 3.
R1 Therapeutics is debuting with…
R1 Therapeutics is debuting with an oversubscribed $77.5 million Series A financing aimed at advancing its first-in-class therapy for hyperphosphatemia in patients on dialysis with chronic kidney disease (CKD).
In a 14-month follow-up, Sana…
In a 14-month follow-up, Sana Biotechnology has found that its investigational allogeneic cell therapy continued to produce insulin for one patient with Type 1 diabetes, with no safety concerns reported.
Inovio Pharmaceuticals has laid…
Inovio Pharmaceuticals has laid off staff and prioritized programs to focus on its lead rare disease candidate, which is already facing some pushback from the FDA early in its approval review.
Immutep and the Australian…
Immutep and the Australian biotech’s investors have been caught off guard by the unexpected failure of its LAG-3 candidate in a phase 3 study.
Years after BioNTech’s CEO Uğur…
Years after BioNTech’s CEO Uğur Şahin, M.D. and chief medical officer Özlem Türeci, M.D., spearheaded the company through the roaring commercial success of Pfizer-partnered COVID-19 vaccine Comirnaty, the duo is preparing to take their hands
Artificial intelligence (AI) now…
Artificial intelligence (AI) now features prominently in boardroom and executive discussions across the life sciences industry. The attention is understandable: AI has the potential to fundamentally reshape how companies discover, develop and deliver new therapies.
As pharmas like Eli Lilly and…
As pharmas like Eli Lilly and Roche bolster their biotech offerings, Pfizer is snuffing out its program designed to incubate new innovations from select companies, dubbed Pfizer Ignite.
Vistagen Therapeutics is doubling…
Vistagen Therapeutics is doubling down on its lead social anxiety candidate, even after the asset failed a phase 3 trial last December. The Bay Area biotech is laying off about 20% of its staff to
An Ultragenyx gene therapy has…
An Ultragenyx gene therapy has scored a win at the midway point of its phase 3 trial, successfully reducing ammonia levels in patients with a rare urea cycle disorder.
Small molecules make up almost…
Small molecules make up almost half of the 20 most valuable orphan drugs in development across biopharma, according to an Evaluate analysis.
BridgeBio Pharma has taken another…
BridgeBio Pharma has taken another step toward the potential approval of its muscle weakness drug candidate BBP-418, reporting statistically significant phase 3 efficacy data that analysts called impressive.
Novo Holdings saw its assets…
Novo Holdings saw its assets shrink by a third last year as part of the fallout of Novo Nordisk’s nosediving share price.
Regenxbio has guided its Duchenne…
Regenxbio has guided its Duchenne muscular dystrophy gene therapy candidate through another test, reporting a clean safety profile and functional improvements as it heads toward pivotal data.